SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is trending due to intensifying acquisition speculation involving major tech titans, with community discourse fueled by leaked reports of Amazon buyout discussions and competing interests from SpaceX. Investors are actively debating the company's valuation, the strategic importance of its proprietary satellite spectrum, and the complex, multi-layered partnerships that make it a critical asset in the race for global direct-to-device connectivity.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing intense market activity as it prepares to join the S&P 500, triggering massive, price-insensitive buying from passive index funds. The community is heavily divided between bulls highlighting the company's critical role in AI-driven optical infrastructure and skeptics who warn of extreme valuations and potential over-extension.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant downward pressure as disappointing delivery figures for the first quarter highlight growing concerns over demand and inventory buildup. The community remains deeply divided, with bears pointing to slowing EV sales and fading brand sentiment, while bulls continue to pivot the narrative toward the company's long-term ambitions in AI, robotics, and the potential impact of a future SpaceX IPO.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing increased investor interest and price momentum driven by strong fourth-quarter 2025 earnings, which highlighted significant operational EBITDA growth, a strengthened balance sheet, and a successful debt-reduction strategy. The community is actively discussing the stock's potential as a domestic pharmaceutical manufacturing play, fueled by speculation surrounding future FDA pre-check pilot program participation and possible government contracts.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant market interest following a major deal to regain full ownership of its Ireland-based Fab 34 facility, a move signaling long-term manufacturing confidence despite broader semiconductor sector volatility. The community is actively debating the company's aggressive capital strategy, weighing the potential for an earnings turnaround against ongoing concerns regarding market manipulation and macroeconomic pressures.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Investors in KELYB are intensely focused on a potential short squeeze fueled by an extremely low float of approximately 255,000 shares and significant insider accumulation, with many holding out for an earnings catalyst next week to trigger a rebound. Despite recent price volatility and concerns over manipulation, the community remains divided between those calling for patience for a parabolic run and others warning of a trap following a sharp pullback from recent highs.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is facing downward pressure amid significant market volatility and high-profile security incidents within its ecosystem, leading to intense debate among community members about its long-term viability. While some investors view the current price action as a buying opportunity, others are actively rotating into alternative networks or stable ETFs due to concerns over network stability and crypto-market momentum.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh an upcoming earnings report against broader volatility in the cannabis sector, with community discussion intensely focused on potential federal rescheduling news and skepticism surrounding management's performance. While some participants are anticipating a positive breakout fueled by a turnaround strategy and analyst upgrades, others remain deeply critical of share dilution and the stock's long-term performance.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is currently trending as investors speculate on its potential for a regulatory rebound following a previous FDA complete response letter (CRL) for its RP1 treatment in advanced melanoma. The community is heavily divided, with intense debate centered on the upcoming Type A meeting, the potential for an expedited path forward despite high hurdles, and significant high-risk activity in the options market as traders weigh the binary outcome of its long-term development plans.

SBA Communications Corp. is a real estate investment trust, which engages in the provision of wireless communications infrastructures. It operates through the following business segments: Domestic Site Leasing, International Site Leasing, and Site Development. The Domestic Site Leasing segment includes AT&T, Sprint, T-Mobile, and Verizon Wireless. The International Site Leasing segment acquires and develops towers. The Site Development segment is involved in consulting and construction activities. The company was founded by Steven E. Bernstein in 1989 and is headquartered in Boca Raton, FL.

SBA Communications Corp - Ordinary Shares - Class A

SBA Communications is currently attracting attention due to circulating buyout rumors and ongoing speculation regarding potential consolidation in the wireless infrastructure sector. While investors remain focused on the company's long-term 5G tailwinds and site leasing durability, community discourse is heavily weighed by concerns over high debt levels and the impact of interest rates on future profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?

GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Shares of GeoVax Labs Inc. (<a class="mention" data-mention="$GOVX" data-symbol-id="GOVX" href="https://stocktwits.com/symbol/GOVX" target="_blank">$GOVX</a>), SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), and Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>) gained in mid-day trading on Friday after the World Health Organisation (WHO) reaffirmed that the ongoing upsurge of mpox remains a public health emergency of international concern (PHEIC).Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus.&nbsp;“The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners,” the apex health agency said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WHO/status/1860015125463175343">post</a> on X (formerly Twitter).&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_132250_27d9a22ffc.png" alt="Screenshot 2024-11-22 132250.png">The WHO first declared mpox a PHEIC in August earlier this year because a new strain of the virus, Clade Ib, had spread to countries that had not previously reported any incidences of the disease, like Thailand and Sweden.&nbsp;Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.&nbsp;<stembedurl>https://stocktwits.com/gabbs/message/593724551</stembedurl>Meanwhile, shares of SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), developing an investigational drug for treating mpox called tecovirimat (TPOXX),&nbsp; jumped 2.5% after the news.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134247_8c8f14c041.png" alt="Screenshot 2024-11-22 134247.png">Retail sentiment around the stock improved to ‘bullish’ (60/100) from ‘neutral’ a day ago.&nbsp;SIGA Technologies’ shares have gained 11% this year so far.There was less movement around Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>), also working on a vaccine for mpox, which saw a marginal uptick of 0.6% in mid-day trading on Friday.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134547_d67811671e.png" alt="Screenshot 2024-11-22 134547.png">Retail sentiment around the stock remained in the ‘neutral’ zone with no significant change in chatter.&nbsp;Emergent Biosolutions’ vaccine, approved for smallpox, has also been used as a mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.<stembedurl>https://stocktwits.com/WinstonSmith33/message/593679534</stembedurl>In 2022, the company acquired the rights to a smallpox treatment called Tembexa, which was developed by Chimerix Inc. ($CMRX), for up to $337.5 million plus royalties.Chimerix was up around 0.6% as well during mid-day trading.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/agrify-stock-doubles-to-hit-over-1-year-high-after-25-9-m-placement-but-retail-wary-of-short-covering-rally/cJIdTKHRg3">Agrify Stock Doubles To Hit Over 1-Year High After $25.9M Placement, But Retail Wary Of Short-Covering Rally</a>

Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus. | Source: Pexels

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 

Equity

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 


The recent mpox outbreak has caused some worries, but has directed market attention toward U.S. vaccine and drug developers. Here's a breakdown of American pharma contenders grabbing the most retail investor interest over the past week:GeoVax Labs Inc (GOVX): Having risen nearly 230% in a week, GOVX is the runaway leader in terms of gains. During the same period, the number of Stocktwits followers of the stock jumped 18% and message volume soared 5,216%.However, the pre-market price tumbled on Tuesday after a share dilution agreement. While Geovax currently has no marketed products, it <a href="https://stocktwits.com/news/markets/equity/geovax-labs-stock-soars-as-mpox-worries-grow/c7vV0nJRTF">has published research</a> suggesting its vaccines could combat mpox and expanded its license to include the virus in December 2023.Additionally, brokerage Roth MKM reportedly believes Geovax's GEO-MVA vaccine could be the first product to market for mpox.Emergent Biosolutions Inc (EBS): With 77% weekly gains, EBS has seen its Stocktwits sentiment shift to ‘extremely bullish’ (92/100) with high message volume, after the company responded to the WHO's call for vaccine manufacturers to submit its product for Emergency Use Listing (EUL) consideration.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/EBS_sentiment_and_message_volume_Aug_20_premarket_0a11af5751.png" alt="EBS sentiment and message volume Aug 20 premarket.png" width="1310" height="316"><figcaption>EBS sentiment and message volume Aug 20 premarket</figcaption></figure>“As the WHO has declared, the mpox outbreak is a public health emergency of international concern, and Emergent is ready to scale up response efforts and partner with U.S. and global public health leaders," said Emergent CEO Joe Papa.<stembedurl>https://stocktwits.com/money1800/message/583452669</stembedurl>&nbsp;Emergent's existing smallpox vaccine is used off-label for mpox, but a formal FDA approval for mpox use is pending.SIGA Technologies Inc (SIGA): SIGA is up 14% over the week, but has lost some momentum after its mpox drug failed to meet a primary study goal.However, the company maintains the drug is available for use under compassionate use protocols. Retail sentiment remains ‘bullish’ (68/100) on Stocktwits, albeit lower than last week.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SIGA_sentiment_and_message_volume_Aug_20_premarket_d9adbdd32b.png" alt="SIGA sentiment and message volume Aug 20 premarket.png" width="1310" height="316"><figcaption>SIGA sentiment and message volume Aug 20 premarket</figcaption></figure>Tonix Pharmaceuticals Holding Corp (TNXP): Having declined 14% over the past week, TNXP has reiterated its commitment to develop its mpox vaccine, TNX-801.However, a Q2 earnings miss and user pessimism on Stocktwits have driven sentiment into "extremely bearish" (12/100) territory.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TNXP_sentiment_and_message_volume_Aug_20_premarket_1856547dea.png" alt="TNXP sentiment and message volume Aug 20 premarket.png" width="1310" height="316"><figcaption>TNXP sentiment and message volume Aug 20 premarket</figcaption></figure>

Colorized transmission electron micrograph of mpox virus particles

Emergent, Geovax, Tonix, Siga: Which Mpox-Linked Stocks Are Retail Investors Most Excited About?

Retail investors are ‘extremely bullish’ on Emergent Biosolutions as it expressed readiness to scale up response efforts for the WHO health emergency.

Among the four U.S.-listed pharma stocks, retail investors are ‘extremely bullish’ on Emergent Biosolutions as it expressed readiness to scale up response efforts for the WHO health emergency.

<h1>These Three Stocks are Experiencing an Outbreak– Or a Breakout Depending How you Look at it</h1><h3>Monkeypox Outbreak Fuels Surge in Related Biopharma Stocks</h3>The recent resurgence of monkeypox has sparked widespread concern and reignited the market's interest in companies working to combat viral diseases. As the outbreak spreads, parallels to the COVID-19 pandemic are being drawn in both the media and financial markets. During the COVID-19 crisis, pharmaceutical companies that developed vaccines, treatments, and diagnostics experienced unprecedented growth, with investors flocking to these stocks in search of gains. Now, as the world faces another potential health emergency, a new set of companies is stepping into the spotlight.The global health community and investors alike are keeping a close eye on monkeypox, a disease caused by the monkeypox virus, which shares similarities with smallpox. While the outbreaks have been sporadic and relatively contained in the past, recent concerns have shifted focus toward vaccine and treatment development. The monkeypox market, although smaller in scope than COVID-19, holds significant potential. The World Health Organization and public health bodies are calling for increased awareness, testing, and vaccination. As a result, companies developing monkeypox-related therapies and vaccines are seeing their stock prices soar.Three such companies—GeoVax Labs, Tonix Pharmaceuticals, and Chimerix—are garnering substantial interest. All three have ties to the smallpox market, which, in turn, gives them relevance in the monkeypox conversation. Below is a review of these companies, their roles in combating the outbreak, and their stock performance over the short, medium, and long term.<a href="https://wealthyvc.com/featured/tiny-healthcare-stock-with-35-million-market-cap-becomes-major-player-overnight-in-rapidly-growing-1-billion-market/">This Tiny Healthcare Stock With $35M Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Blood Clot Market</a><a href="https://stocktwits.com/symbol/GOVX">GeoVax Labs (NASDAQ: GOVX)</a>GeoVax Labs has emerged as one of the frontrunners in the monkeypox vaccine race. Based in Georgia, this clinical-stage biotechnology company specializes in vaccines that leverage its proprietary Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) platform. The company has been developing vaccines for various infectious diseases, including smallpox, Ebola, and Lassa fever. However, with the recent monkeypox outbreak, GeoVax's focus on viral hemorrhagic fevers and poxvirus diseases has become particularly relevant.GeoVax's stock soared as concerns around monkeypox escalated, with investors seeing potential in its MVA-based vaccine technology. Its smallpox vaccine is designed to offer cross-protection against monkeypox due to the close relation between the two viruses. This has made GeoVax a significant player in the biopharma space, as public health agencies explore all options for controlling the spread of the virus.<ul><li>1-Day Return: +33%</li><li>1-Month Return: +234%</li><li>1-Year Return: +21%</li></ul>GeoVax shares have experienced strong upward momentum over the past month, driven by mounting concerns over monkeypox. Over the past year, the stock has gained substantial value as the company has positioned itself as a leader in the viral vaccine space.<a href="https://stocktwits.com/symbol/TNXP">Tonix Pharmaceuticals (NASDAQ: TNXP)</a><a href="https://stocktwits.com/symbol/TNXP"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_19_at_9_53_43_PM_2ed6d91698.png" alt="Screenshot 2024-08-19 at 9.53.43 PM.png"></a>Tonix Pharmaceuticals, another biotech firm in the spotlight, is developing live virus vaccines that may offer protection against monkeypox and other orthopoxvirus diseases. Based in New Jersey, Tonix has focused on immunology, chronic diseases, and rare infectious diseases. One of its notable projects is its live virus vaccine candidate, TNX-801, designed to protect against both smallpox and monkeypox.A recent Benzinga article highlighted the company’s preclinical results, which demonstrated long-term immunity and protection against these viruses. Tonix’s TNX-801 is based on a horsepox viral platform, which is closely related to smallpox and monkeypox. The company is working on creating a robust, durable immune response that can withstand mutations and future outbreaks. What makes Tonix attractive is the potential for TNX-801 to be used as a preventive measure in populations at high risk of contracting monkeypox.<ul><li>1-Day Return: +40%</li><li>1-Month Return: +12%</li><li>1-Year Return: -98%</li></ul>Tonix Pharmaceuticals has seen a notable rise in its stock price over the past month, as interest in its vaccine candidate has intensified. However, the stock’s performance over the past year reflects the inherent volatility in biotech investing, with a significant drop amid broader market conditions and uncertainty in the clinical trial space.<a href="https://stocktwits.com/symbol/CMRX">Chimerix, Inc. (NASDAQ: CMRX)</a><a href="https://stocktwits.com/symbol/CMRX"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_19_at_9_54_50_PM_c72f46e0e8.png" alt="Screenshot 2024-08-19 at 9.54.50 PM.png"></a>Chimerix, Inc., a biotechnology company based in North Carolina, is another name linked to the monkeypox outbreak. While the company gained attention for its smallpox drug, Tembexa, the renewed interest in orthopoxviruses like monkeypox has brought Chimerix back into the conversation. Tembexa (brincidofovir) is an FDA-approved treatment for smallpox, which gives Chimerix an edge as governments explore stockpiling options for poxvirus diseases.Though Chimerix has not explicitly developed a monkeypox treatment, the parallels between smallpox and monkeypox suggest that Tembexa could play a role in mitigating the effects of the outbreak. The drug's broad-spectrum antiviral activity makes it a candidate for off-label use in monkeypox cases. In a market where few treatments exist, Chimerix’s existing FDA approval for Tembexa may provide a quicker pathway for emergency use if the monkeypox crisis intensifies.<ul><li>1-Day Return: +5%</li><li>1-Month Return: +20%</li><li>1-Year Return: +14%</li></ul>Chimerix’s stock has seen a short-term bump as investors reevaluate its smallpox drug in light of the monkeypox outbreak. However, much like Tonix, the stock’s performance over the past year has been challenging, marked by sell-offs and investor uncertainty around the company’s long-term prospects.ConclusionAs monkeypox continues to spread, the market is once again turning to biopharmaceutical companies for solutions.&nbsp;GeoVax Labs,&nbsp;Tonix Pharmaceuticals, and&nbsp;Chimerix Inc. are at the forefront of efforts to address this public health crisis, each leveraging its expertise in smallpox and viral disease research. While the global market for monkeypox treatments is still emerging, these companies are well-positioned to capture the growing demand for vaccines and antiviral treatments.Investors should keep a close eye on clinical developments, regulatory approvals, and government stockpiling programs, as these will be key drivers of stock performance in the coming months. Like the COVID-19 pandemic, the monkeypox outbreak has the potential to create significant winners in the biotech sector. However, as always with biopharma stocks, the risks are high, and careful due diligence is necessary before jumping into this volatile space.&nbsp;Read Next:&nbsp;<a href="https://wealthyvc.com/featured/tiny-healthcare-stock-with-35-million-market-cap-becomes-major-player-overnight-in-rapidly-growing-1-billion-market/">This Tiny Healthcare Stock With $35M Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Blood Clot Market</a><a href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;<a href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>This article is from an unpaid external contributor. It does not represent Stocktwits reporting or views and has not been edited for content or accuracy.&nbsp;&nbsp;

These Three Stocks are Experiencing an Outbreak– Or a Breakout Depending How you Look at it

GeoVax Labs, Tonix Pharmaceuticals, and Chimerix see stock surge amid monkeypox outbreak, leveraging their expertise in viral diseases and smallpox-related vaccines.

Monkeypox Outbreak Boosts These Biopharma Stocks

The monkeypox outbreak has boosted stocks of GeoVax Labs, Tonix Pharmaceuticals, and Chimerix. These companies are developing vaccines and treatments related to smallpox and viral diseases, positioning them as key players in addressing this health crisis.

<a href="https://stocktwits.com/symbol/GOVX">Geovax Labs</a> (GOVX) is currently the hottest stock on Stocktwits, with shares surging over 56% in pre-market trading on Monday. Notably, the rally follows a near 111% rise in the stock price on Friday.The company’s new retail followers on Stocktwits jumped by 9% and message volume exploded by over 8,300% in the past week.This meteoric rise is largely attributed to the increased focus on mpox following the World Health Organization's declaration of a global health emergency. The European Centre for Disease Prevention and Control (ECDC) has also issued a new risk assessment, further fueling concerns about the disease.Geovax has positioned itself as a potential key player in the fight against mpox. The company previously published research suggesting its vaccines could help prevent the disease and expanded its commercial license to include mpox and smallpox in December 2023.Brokerage Roth MKM reportedly believes Geovax's GEO-MVA vaccine could be the first product to market for mpox.In contrast, Siga Technologies (SIGA), an earlier frontrunner in the mpox treatment space,saw its stock decline over 2% in Monday’s premarket session. This follows disappointing top-line results from a trial testing its TPOXX drug for mpox. While the drug showed some clinical benefits, it failed to meet its primary endpoint.Interestingly, despite the setback, retail investor sentiment for SIGA on Stocktwits has surprisingly flipped to ‘extremely bullish’ territory (93/100), suggesting hopes for a turnaround.<figure class="image"><img style="aspect-ratio:1320/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SIGA_sentiment_and_message_volume_Aug_19_premarket_25843ab158.png" alt="SIGA sentiment and message volume Aug 19 premarket.png" width="1320" height="318"><figcaption>SIGA sentiment and message volume Aug 19 premarket</figcaption></figure>While both companies are in the spotlight due to the mpox outbreak, Geovax has clearly captured more retail investor attention for now.<stembedurl>https://stocktwits.com/RWROCKPORT/message/583340518</stembedurl>&nbsp;Year-to-date, GOVX has gained over 27%, while SIGA is up 80%.

Geovax previously published research suggesting its vaccines could help prevent mpox.

Geovax Labs Stock Keeps Soaring, Grabs Most Retail Attention As Mpox Concerns Grow

With another health agency issuing alerts about the rapidly spreading disease similar to smallpox, GOVX stock has seen its stock surge by more than 270% in the past week.

With another health agency issuing alerts about the rapidly spreading disease similar to smallpox, GOVX has seen its stock surge by more than 270% in the past week.


Siga Technologies (SIGA), a pharmaceutical company specializing in treatments for smallpox and related diseases, saw its stock surge nearly 27% on Wednesday as the World Health Organization (WHO) declared Mpox a public health emergency of international concern, leading to a spike in retail investor interest.Following the WHO announcement, SIGA became the stock that added the most new watchers on Stocktwits in the last 24 hours. Retail investor sentiment turned ‘extremely bullish’ with a score of 95 out of 100, while message volume peaked at its highest level this year (97/100).<figure class="image"><a href="https://stocktwits.com/symbol/SIGA"><img style="aspect-ratio:1320/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SIGA_sentiment_and_message_volume_Aug_15_premarket_5de8758c81.png" alt="SIGA sentiment and message volume Aug 15 premarket.png" width="1320" height="318"></a><figcaption>SIGA sentiment and message volume Aug 15 premarket</figcaption></figure>The rise in Mpox cases in Africa prompted the WHO's declaration, sparking renewed interest in pharmaceutical stocks linked to the disease. SIGA is particularly well-positioned as its antiviral drug, TPOXX (tecovirimat), has been used to treat Mpox, especially in severe cases.Last month, the company's stock received a boost after the U.S. Department of Health and Human Services exercised a $113 million contract option for oral TPOXX treatments.<stembedurl>https://stocktwits.com/goodupsidestockfinder/message/582972463</stembedurl>Adding to the optimism, SIGA reported strong Q2 financial results earlier this month, swinging to a profit with revenue surging from $5.88 million to $21.81 million.<a href="https://stocktwits.com/symbol/GOVX">GeoVax Labs</a> (GOVX), another pharmaceutical company, saw its stock price rise 30% on Wednesday following the WHO announcement.In December 2023, GOVX expanded its commercial license to include Mpox and smallpox through an agreement with the National Institute of Allergy and Infectious Diseases. This ticker is also garnering a lot of retail attention on the WHO’s announcement.<stembedurl>https://stocktwits.com/GOVXBULL/message/582978461</stembedurl>

SIGA's antiviral drug, TPOXX (tecovirimat), has been used to treat Mpox, especially in severe cases. Representative image via Vecteezy

Siga Technologies Stock Adds Most New Retail Watchers After WHO Declares Mpox Health Emergency

Retail investor sentiment on Stocktwits turned 'extremely bullish' with message volume reaching its highest level this year.

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Geovax Labs Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

GOVX
Geovax Labs Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GOVX News

GOVXGeovax Labs Inc